Get ready for M&A: Large biopharma companies will have $1.7T in dealmaking firepower next year, analyst says

Merger and acquisition activity has been rather slow in the biopharma industry so far this year. But, by one team of analysts’ calculations, large drugmakers will have big piles of cash to deploy in 2022.